Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor

References

• Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, et al., Working Group on On-Treatment Platelet R. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62:2261–2273.
   Google Scholar
• Siller-Matula JM, Trenk D, Schror K, Gawaz M, Kristensen SD, Storey RF, Huber K. How to improve the concept of individualized antiplatelet therapy with p2y12 receptor inhibitors – Is an algorithm the answer? Thromb Haemost 2014;1:37–52.
   Web of Science ®Google Scholar
• Schror K, Siller-Matula JM, Huber K. Pharmacokinetic basis of the antiplatelet action of prasugrel. Fundam Clin Pharmacol 2012;26:39–46.
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Jilma B. Ticagrelor: From discovery to phase III clinical trial. Future Cardiol 2010;6:753–764.
   PubMedGoogle Scholar
• Bonello L, Pansieri M, Mancini J, Bonello R, Maillard L, Barnay P, Rossi P, Ait-Mokhtar O, Jouve B, Collet F, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011;58:467–473.
   PubMed Web of Science ®Google Scholar
• Michelson AD, Frelinger AL, 3rd, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. Clopidogrel in the triton-timi 38 trial. Eur Heart J 2009;30:1753–1763.
   PubMed Web of Science ®Google Scholar
• Bonello L, Mancini J, Pansieri M, Maillard L, Rossi P, Collet F, Jouve B, Wittenberg O, Laine M, Michelet P, et al. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at one year follow-up in patients receiving prasugrel. J Thromb Haemost 2012;10:1999–2005
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012;5:797–804.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Davlouros P, Plakomyti TE, Panagiotou A, Mavronasiou E, Hahalis G. Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. Am Heart J 2011;162:733–739.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Panagiotou A, Xanthopoulou I, Komninakis D, Kassimis G, Davlouros P, Fourtounas C, Goumenos D. Antiplatelet effects of prasugrel vs double clopidogrel in patients on hemodialysis and high on-treatment platelet reactivity. J Thromb Haemost 2011;9:2379–2385.
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Trenk D, Schror K, Gawaz M, Kristensen SD, Storey RF, Huber K. Response variability to p2y12 receptor inhibitors: Expectations and reality. JACC Cardiovasc Interv 2013;6:1111–1128.
   PubMed Web of Science ®Google Scholar
• Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, Ten Berg J, Janssen P, Angiolillo DJ, et al. Bleeding and stent thrombosis on p2y12-inhibitors: Collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015; 14:1762–1771.
   Google Scholar
• Siller-Matula JM, Lang IM, Neunteufl T, Kozinski M, Maurer G, Linkowska K, Grzybowski T, Kubica J, Jilma B. Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention. PLoS One 2014;9:e102701.
   PubMed Web of Science ®Google Scholar
• Mayer K, Orban M, Bernlochner I, Braun S, Schulz S, Gross L, Hadamitzky M, Schunkert H, Laugwitz KL, Massberg S, et al. Predictors of antiplatelet response to prasugrel during maintenance treatment. Platelets 2014;26:53–58.
   PubMed Web of Science ®Google Scholar
• Dridi NP, Johansson PI, Clemmensen P, Stissing T, Radu MD, Qayyum A, Pedersen F, Helqvist S, Saunamaki K, Kelbaek H, et al. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response – The tailor (thrombocytes and individualization of oral antiplatelet therapy in percutaneous coronary intervention) randomized trial. Platelets 2013;25:506–512.
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Francesconi M, Dechant C, Jilma B, Maurer G, Delle-Karth G, Gouya G, Ruzicka K, Podczeck-Schweighofer A, Christ G. Personalized antiplatelet treatment after percutaneous coronary intervention: The madonna study. Int J Cardiol 2013;167:2018–2023.
   PubMed Web of Science ®Google Scholar
• Ibrahim K, Christoph M, Schmeinck S, Schmieder K, Steiding K, Pfluecke C, Quick S, Mues C, Jellinghaus S, Wunderlich C, et al. High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation 2014; 85:649–656.
   Google Scholar
• Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: A pharmacodynamic study. J Am Coll Cardiol 2012;60:193–199.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Curzen N, Gurbel P, Vaitkus P, Lipkin F, Li W, Jakubowski JA, Zettler M, Effron MB, Trenk D. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in subjects with stable coronary artery disease: Results of the swap-2 study. J Am Coll Cardiol 2014;63:1500–1509.
   Google Scholar
• Deharo P, Bassez C, Bonnet G, Pankert M, Quilici J, Lambert M, Verdier V, Morange P, Alessi MC, Bonnet JL, Cuisset T. Prasugrel versus ticagrelor in acute coronary syndrome: A randomized comparison. Int J Cardiol 2013;170:e21–e22.
   PubMed Web of Science ®Google Scholar
• Tomizawa A, Ohno K, Jakubowski JA, Mizuno M, Sugidachi A. Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an elisa-based vasp phosphorylation assay and platelet aggregation. Thromb Haemost 2013;110:769–776.
   PubMed Web of Science ®Google Scholar